ERBB2 and non-small cell lung carcinoma: But trastuzumab combined with paclitaxel are currently assessing in a phase II clinical study (NCT02226757) as a treatment strategy in EGFR-mutant NSCLC patients developed HER2 activation (HER2 immunohistochemistry (IHC) ≥ 1) as acquired resistance mechanism to EGFR-TKIs.